oral semaglutide results The Pros and Cons of for Weight Loss Safety and Pharmacokinetics of Single

A., Harbaugh, A

Figure 1: GLP-1/incretin competitive pipeline

1 Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly referred to as non-alcoholic fatty liver disease (NAFLD), has become the most prevalent chronic liver condition worldwide, affecting approximately one-third to nearly 40% of the adult population globally, with projections indicating an increase to over 55% by 2040 ( (THR-) agonist, received approval from the FDA in 2024 for the treatment of adult patients with F2-F3 MASH ( Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have gained considerable attention in recent years as promising therapeutic agents for MASLD, particularly owing to their well-established efficacy in treating type 2 diabetes mellitus (T2DM) and obesity, conditions closely implicated to MASLD pathogenesis ( This review aims to systematically summarize the mechanistic insights and clinical advances of GLP-1with dual or triple receptor agonists in MASLD treatment, thereby promoting a more profound comprehension and facilitating their application in clinical practice (Figure 1)

On Monday, the Lancet Gastroenterology and Hepatology published new research estimating that 1.3 billion people worldwide had MASLD in 2023 a figure projected to balloon to 1.8 billion by 2050, largely driven by population growth

doi: 10.1038/s12276-018-0084-3 29 KangZ.ZengJ.ZhangT.LinS.GaoJ.JiangC.et al

Heres what experts want you to know about skipping a semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) dose, including potential side effects, risks, and how to get back on track